Glycochenodeoxycholate promotes IL-8 expression through ER–mitochondrial calcium signaling in human hepatocytes
Biochemical and Biophysical Research Communications · 2026-11 · 840 · 154759
DOI: 10.1016/j.bbrc.2026.154759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-11. Verfasst von Tomoya Hirai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8675, Japan. Hauptthemen laut MEDLINE: Hepatocytes, Endoplasmic Reticulum, Calcium Signaling, Glycochenodeoxycholic Acid. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Accumulation of excessive bile acids in the liver contributes to the progression of liver injury; thus, elucidating the bile acid-induced responses remains a critical challenge. Although conjugated bile acids have recently been reported to induce inflammatory responses at non-cytotoxic concentrations, the precise molecular mechanisms involved are not fully understood. The present study investigated the role of intracellular calcium dynamics-focusing particularly on mitochondria-in bile acid-induced inflammatory signaling. Exposure of human hepatocytes isolated from humanized liver chimeric mice (HepaSH cells) to glycochenodeoxycholate (GCDCA), a major component of the human bile acid pool, induced IL-8 mRNA expression at non-cytotoxic concentrations. This induction was significantly suppressed by 2-APB, an inhibitor of inositol 1,4,5-trisphosphate receptors on the endoplasmic reticulum. To clarify the underlying mechanisms, intracellular calcium measurements using fluorescent probes revealed no prominent changes in global cytosolic calcium levels; instead, GCDCA induced a marked increase in mitochondrial calcium levels, which was attenuated by 2-APB co-treatment. Overall, our findings highlight the critical role of mitochondria-centered calcium regulation in bile acid-induced inflammatory responses, providing novel insights into the pathogenesis of cholestatic liver injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8675, Japan.
- Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8675, Japan. Electronic address: a-takemura@chiba-u.jp.
- Central Institute for Experimental Medicine and Life Science, Tonomachi 3-25-12, Kawasaki-ku, Kawasaki, 210-0821, Japan.
- Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8675, Japan. Electronic address: itokousei@chiba-u.jp.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Hirai, T., Takemura, A., Higuchi, Y., Uehara, S., Yoneda, N., Suemizu, H., & Ito, K. (2026). Glycochenodeoxycholate promotes IL-8 expression through ER–mitochondrial calcium signaling in human hepatocytes. Biochemical and Biophysical Research Communications, 840, 154759. https://doi.org/10.1016/j.bbrc.2026.154759
Vancouver
Hirai T, Takemura A, Higuchi Y, Uehara S, Yoneda N, Suemizu H, et al. Glycochenodeoxycholate promotes IL-8 expression through ER–mitochondrial calcium signaling in human hepatocytes. Biochemical and Biophysical Research Communications. 2026;840:154759. doi:10.1016/j.bbrc.2026.154759
BibTeX
@article{Hirai2026,
author = {Hirai, Tomoya and Takemura, Akinori and Higuchi, Yuichiro and Uehara, Shotaro and Yoneda, Nao and Suemizu, Hiroshi and Ito, Kousei},
title = {Glycochenodeoxycholate promotes IL-8 expression through ER–mitochondrial calcium signaling in human hepatocytes},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {840},
pages = {154759},
doi = {10.1016/j.bbrc.2026.154759}
}
EUVIMED